Skip to main content

Table 4 The combined effect of serum urate and high sensitive C-reactive protein with all-cause and cause-specific mortality

From: Repeated measurements of serum urate and mortality: a prospective cohort study of 152,358 individuals over 8 years of follow-up

 

Low hs-CRP low serum urate

Low hs-CRP hyperuricemia

High hs-CRP low serum urate

High hs-CRP hyperuricemia

P for interaction

All-cause mortality

 Population no. (cases)

110,643 (4717)

7577 (386)

20,381 (2023)

2825 (275)

 

 Incidence rate, per 1000 person-years

5.50

7.31

13.5

14.4

 

 Age- and sex-adjusted HR

1 (ref)

1.20 (1.08–1.33)

1.65 (1.57–1.74)

1.82 (1.61–2.06)

0.29

 Multiple adjusted HR*

1 (ref)

1.16 (1.04–1.29)

1.49 (1.41–1.57)

1.56 (1.37–1.76)

0.20

 In 121,110 men HR*

1 (ref)

1.16 (1.04–1.30)

1.51 (1.42–1.59)

1.51 (1.32–1.73)

0.09

 In 30,081 women HR*

1 (ref)

0.95 (0.63–1.43)

1.25 (1.02–1.54)

1.79 (1.23–2.62)

0.14

Cardiovascular mortality

 Population no. (cases)

110,643 (1055)

7577 (109)

20,381 (481)

2825 (74)

 

 Incidence rate, per 1000 person-years

1.23

2.06

3.21

3.88

 

 Multiple adjusted HR*

1 (ref)

1.36 (1.11–1.67)

1.44 (1.28–1.61)

1.55 (1.21–1.97)

0.15

 In 121,110 men HR*

1 (ref)

1.39 (1.12–1.71)

1.43 (1.27–1.61)

1.46 (1.12–1.90)

0.07

 In 30,081 women HR*

1 (ref)

1.05 (0.47–2.36)

1.40 (0.92–2.13)

2.49 (1.25–4.97)

0.32

Cancer mortality

 Population no. (cases)

110,643 (1148)

7577 (57)

20,381 (437)

2825 (41)

 

 Incidence rate, per 1000 person-years

1.34

1.08

2.91

2.15

 

 Multiple adjusted HR*

1 (ref)

0.75 (0.57–0.98)

1.54 (1.38–1.73)

1.17 (0.85–1.60)

0.96

 In 121,110 men HR*

1 (ref)

0.77 (0.58–1.02)

1.55 (1.38–1.75)

1.05 (0.74–1.50)

0.58

 In 30,081 women HR*

1 (ref)

0.43 (0.13–1.40)

1.32 (0.89–1.97)

1.91 (0.87–4.20)

0.08

Other mortalities

 Population no. (cases)

110,643 (963)

7577 (94)

20,381 (417)

2825 (58)

 

 Incidence rate, per 1000 person-years

1.12

1.78

2.78

3.04

 

 Multiple adjusted HR*

1 (ref)

1.48 (1.19–1.84)

1.53 (1.35–1.72)

1.77 (1.34–2.33)

0.16

 In 121,110 men HR*

1 (ref)

1.42 (1.13–1.79)

1.54 (1.36–1.75)

1.82 (1.37–2.42)

0.32

 In 30,081 women HR*

1(ref)

1.84 (0.88–3.85)

1.33 (0.85–2.09)

1.30 (0.44–3.81)

0.32

  1. Hyperuricemia is defined by a cutoff values of > 7.0mg/dl for men and > 6.0 mg/dl for women
  2. High C-reactive protein is defined as hs-CRP > 3 mg/L.
  3. *Model adjusted for age (year); sex; smoke status (current, past, or never); alcohol consumption status (current, past, or never); physical activity (never, sometimes, or active); average monthly income of each family member (< 500, 500–2999, or ≥ 3000¥); education (illiteracy/elementary school, middle school, or college/university); sodium intake (< 6.0, 6.0–9.9, or ≥ 10.0 g/day); father and mother’s cardiovascular disease history (yes or no); use of aspirin, antihypertensive, hypoglycemic, and lipid-lowering agents (yes/no for each); systolic blood pressure (quintile); diastolic blood pressure (quintile); fasting blood glucose (< 4.0, 4.0–5.5, 5.6–6.9, or ≥ 7 mmol/L); triglycerides (< 1.7, 1.7–2.2, 2.3–5.5, or ≥ 5.6 mmol/L); low-density lipoprotein cholesterol (< 1.80, 1.80–3.33, 3.34–4.91, or ≥ 4.92 mmol/L); body mass index (< 25.0, 25.0–29.9, or ≥ 30 kg/m2); and estimated glomerular filtration rate (< 30, 30–59, 60–89, or ≥ 90 mL/min/1.73 m2)
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us